Not Yet Recruiting
Efficacy and Safety of a Two-week Dosing Regimen of Vinorelbine Combined with Liposomal Doxorubicin in the Treatment of HER2-negative Advanced Breast Cancer
NCT06653972
- Conditions
- HER2-negative Metastatic Breast Cancer, Liposomal Doxorubicin, Vinorelbine
- Locations
-
Not specified